Business in the Burbs

Leukemia & Lymphoma Society to invest $3.7 million in study

January

The Leukemia & Lymphoma Society in White Plains will invest $3.7 million to help study a new treatment for acute myeloid leukemia that is under development by Celator Pharmaceuticals Inc. Celator, based in Princeton, N.J., expects to start patient enrollment in a study of the treatment during the first quarter in the United States and Canada. The treatment, known as CPX-351, is being studied in patients 60 to 75 years old.

This entry was posted on Thursday, January 22nd, 2009 at 3:14 pm by Jay Loomis. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.